Revelation Biosciences, Inc. (REVB) Stock

Revelation Biosciences, Inc. (REVB) is a Healthcare stock trading at $1.08 (as of 2026-08-21), with a market capitalization of $4.32M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company developing immune system therapeutics and related diagnostics. Its development pipeline includes GEM-AKI for acute kidney injury and GEM-CKD for chronic kidney disease.

Valuation — source: SEC EDGAR (first-party)
Price$1.08
Market Cap$4.32M
Price / Book0.43
FCF Yield-288.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$222.00
Net Margin-959741.0%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderARMISTICE CAPITAL, LLC ($387889.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJames Rolke
Employees8
CountryUS
IPO Date2020-11-17

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Pulmatrix, Inc. (PULM)
  • Lakewood-Amedex Biotherapeutics Inc. (LABT)
  • Aptevo Therapeutics Inc. (APVO)
  • FibroBiologics, Inc. Common Stock (FBLG)
  • GRI Bio, Inc. (GRI)
  • Genprex, Inc. (GNPX)
  • Artelo Biosciences, Inc. (ARTL)
  • 60 Degrees Pharmaceuticals, Inc. (SXTP)
REVB earnings history · REVB institutional & insider holders · REVB KPIs & operating metrics · REVB financials · REVB investor presentations & press releases · REVB SEC filings · REVB peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.